# Compare CJC-1295, Ipamorelin, and MOTS-c — Peptide Cycles

> A side-by-side, protocol-level comparison of three Growth Hormone Axis research peptides — CJC-1295, ipamorelin, and MOTS-c — across receptor target, study design, half-life, and key cautions.

How CJC-1295, ipamorelin, and MOTS-c differ in mechanism, study design maturity, measured pharmacokinetics, and the single most important caution the literature attaches to each.

## The short version

This page lines up [CJC-1295](/cjc-1295), [ipamorelin](/ipamorelin), and [MOTS-c](/mots-c) on the dimensions that matter most when reading Growth Hormone Axis peptide research: what receptor or mechanism each acts on, how mature and how large the study protocols behind each one are, what pharmacokinetic numbers (like half-life) have actually been measured in humans, and the single biggest caution attached to each compound. The honest summary is uneven: CJC-1295 has small human pharmacokinetic studies but no efficacy trial; ipamorelin has the most complete human trial record of the three, and that trial did not meet its primary endpoint; MOTS-c has almost no human interventional data at all. None of this is medical advice, and no dose is recommended anywhere on this page.

## The comparison matrix

| Dimension | CJC-1295 | Ipamorelin | MOTS-c |
| --- | --- | --- | --- |
| Primary mechanism | GHRH-receptor (GHRHR) agonist on pituitary somatotrophs [4] | Ghrelin/GHS-R1a receptor agonist, selective for GH release [11] | AMPK activation via CK2 binding and folate-cycle/purine-biosynthesis inhibition [13][17] |
| Longest reported human data | IGF-1 elevation tracked to 28 days post-dose (multi-dose protocol) [4] | Single Phase 2 RCT, up to 7 days of twice-daily dosing [8] | No interventional human data; observational cohort followed a median 26.5 months [14] |
| Measured human half-life | 5.8-8.1 days (estimated, DAC form) [4] | Approximately 2 hours (terminal half-life, IV) [9] | Not established in humans |
| Study-design maturity | Multiple Phase 1 human PK studies; no Phase 2/3 program on record | One completed Phase 2 RCT (primary endpoint not met) [8]; Phase 1 PK study [9]; preclinical work | Cell-culture and rodent studies; human data limited to observational biomarker association [14] |
| Most consistent research finding | Dose-dependent, multi-day GH/IGF-1 elevation replicated across independent PK studies [4][5] | Selective GH release without meaningful ACTH/cortisol elevation, replicated across species [11] | Direct CK2 binding and AMPK-dependent nuclear gene regulation, demonstrated in cells and mice [13][17] |
| Key caution | Sustained IGF-1 elevation (epidemiologic cancer-risk association) and fluid retention | A class-level cardiotoxicity signal from a related (not identical) GHS-R1a agonist [7] | No human pharmacokinetic data exist; rodent-study doses cannot be extrapolated to people |

## Primary mechanism

CJC-1295 and ipamorelin both trigger growth hormone release from the pituitary, but through separate receptors — CJC-1295 via the GHRH receptor [4], ipamorelin via the ghrelin/GHS-R1a receptor [11] — which is the pharmacological logic behind studying and, in some research contexts, combining the two [12]. MOTS-c is mechanistically distinct from both: it does not primarily act through a pituitary hormone receptor at all, instead activating AMPK through direct CK2 binding and folate-cycle inhibition, with downstream nuclear gene-expression effects [13][17]. Only CJC-1295 and ipamorelin converge on GH release as a shared endpoint; MOTS-c's connection to the broader GH/IGF-1 axis is comparatively indirect.

## Study design and protocol maturity

This is where the three compounds separate most sharply. CJC-1295's human evidence consists of small pharmacokinetic studies — single- and multiple-dose protocols in a few dozen healthy adults tracking GH and IGF-1 over days to weeks [3][4][5] — with no Phase 2 or Phase 3 program identified in the literature. Ipamorelin has the single most complete human protocol of the three: a randomized, controlled Phase 2 trial (NCT00672074) in 114 surgical patients, dosed intravenously twice daily for up to 7 days [8], plus a separate acute-dosing PK study in 8 healthy volunteers [9] — but the Phase 2 trial's primary endpoint did not reach statistical significance. MOTS-c's protocol record is the thinnest by a wide margin: repeated-dosing rodent protocols [13][16] and cell-based mechanistic work [17], with the only human data point being an observational cohort in which no MOTS-c was ever administered [14].

## Pharmacokinetics: what's actually been measured

Where PK numbers exist, they diverge sharply by design. CJC-1295's DAC form is engineered for duration — an estimated 5.8-8.1 day elimination half-life, with IGF-1 elevated for up to 28 days after repeated dosing [4]. Ipamorelin is engineered for the opposite: a fast, discrete pulse, with a measured terminal half-life around 2 hours and peak GH response at roughly 40 minutes post-dose [9]. MOTS-c has no published human PK parameters at all — no measured half-life, clearance, or volume of distribution in people — which is a direct consequence of there being no completed human interventional study to measure them in.

## Key caution, compound by compound

Each compound's defining caution follows directly from its evidence gap. For CJC-1295, it is the combination of sustained IGF-1 elevation — a hormone epidemiologically linked to modestly higher cancer risk at the population level — with fluid-retention effects that are well documented mechanistically even though CJC-1295-specific long-term outcome data do not exist. For ipamorelin, it is a class-level cardiotoxicity signal: a 28-day preclinical safety study of a different ghrelin-receptor agonist (GSK894281, not ipamorelin) found dose-dependent myocardial degeneration in rats [7], and no equivalent chronic cardiovascular study of ipamorelin itself has been published in any species. For MOTS-c, the caution is structural rather than mechanistic: there is no measured human pharmacokinetic profile, no completed interventional trial, and therefore no basis for translating any rodent-study dose into a human context. Reading the three side by side, the pattern is less about which compound is "riskiest" and more about how unevenly the underlying research protocols have been built out.

---

A data desk for Growth Hormone Axis peptide research — every number sourced to its study design, no doses recommended, nothing for sale.